Stay updated on Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Pembrolizumab in HCC Clinical Trial page
- Check6 days agoChange DetectedThe site revision was updated from v3.3.3 to v3.3.4, a minor UI/metadata update that does not affect study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedFooter now displays Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedThe change updates the page revision label from v3.2.0 to v3.3.2 in the footer and does not affect study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedDeleted the site-wide notice about potential data currency and government funding impacts that warned users the information might not be up to date. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check77 days agoChange DetectedTwo screenshots show only minor formatting and UI differences on the ClinicalTrials.gov study page, and there are no changes to the core study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check106 days agoChange DetectedAdded a government-operating-status notice and updated software version to v3.2.0, replacing v3.1.0.SummaryDifference4%

Stay in the know with updates to Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HCC Clinical Trial page.